Evidence map›Paper›PMID 38799180›Full record

ArticleJAC-antimicrobial resistance2024

Activity of ceftolozane/tazobactam and imipenem/relebactam against Gram-negative clinical isolates collected in Mexico-SMART 2017-2021.

James A Karlowsky, Sibylle H Lob, Fakhar Siddiqui, Thales Polis, Jose L Vallejo, Katherine Young, Mary R Motyl, Daniel F Sahm

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JAC-antimicrobial resistance, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Global epidemiology of carbapenem-resistantJAC-antimicrobial resistance · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

James A KarlowskyIHMA, 2122 Palmer Drive, Schaumburg, IL 60173, USA.
Sibylle H LobIHMA, 2122 Palmer Drive, Schaumburg, IL 60173, USA.
Fakhar SiddiquiMerck & Co., Inc., 126 East Lincoln Avenue, Rahway, NJ 07065, USA.
Thales PolisMSD Brasil, Av. Chucri Zaidan, 296-Vila Cordeiro, São Paulo 04583-110, Brazil.
Jose L VallejoMSD Mexico, Av. San Jerónimo 369, Tizapán San Ángel, Tizapán, Álvaro Obregón, 01090 Mexico City, Mexico.
Katherine YoungMerck & Co., Inc., 126 East Lincoln Avenue, Rahway, NJ 07065, USA.
Mary R MotylMerck & Co., Inc., 126 East Lincoln Avenue, Rahway, NJ 07065, USA.
Daniel F SahmIHMA, 2122 Palmer Drive, Schaumburg, IL 60173, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: To investigate the activities of ceftolozane/tazobactam and imipenem/relebactam against Methods: MICs were determined by CLSI broth microdilution and interpreted using CLSI M100 breakpoints. β-Lactamase genes were identified in ceftolozane/tazobactam-, imipenem/relebactam-, and/or imipenem-non-susceptible isolates. Results: Ceftolozane/tazobactam and imipenem/relebactam inhibited 89% and 99% of Conclusions: Ceftolozane/tazobactam and imipenem/relebactam may provide treatment options for patients infected with β-lactam-non-susceptible Gram-negative bacilli, excluding isolates carrying an MBL- or OXA-48-like carbapenemase.

Identifiers

PMID38799180
PMCPMC11126326

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.